Although all of the samples studied had been classified based on their Binet stages, CLL diagnosis benefits from new prognostic markers such as IGHv variabilty or del(17p)/TP53 mutational status in CLL patients. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.